Cel-Sci Corporation Common Stock (NY:CVM)

2.310 UNCHANGED

Delayed Quote Updated: 8:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

March 19, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Issues Letter to Shareholders

March 06, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

February 15, 2024

From CEL-SCI Corporation

Via Business Wire

Why CEL-SCI Corporation (CVM) Shares Are Diving ↗

February 09, 2024

CEL-SCI Corporation shares are trading lower by 13.9% Friday morning. The company priced an offering of 3.875 million shares.

Via Benzinga

CVM Stock Earnings: CEL-SCI Reported Results for Q4 2023 ↗

December 27, 2023

CEL-SCI just reported results for the fourth quarter of 2023.

Via InvestorPlace

InvestorNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes on $7.75M Public Offering

February 14, 2024

Via Investor Brand Network

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

February 13, 2024

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 09, 2024

Via Benzinga

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

February 09, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug

February 06, 2024

From CEL-SCI Corporation

Via Business Wire

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

January 31, 2024

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

December 28, 2023

Via Benzinga

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments

December 22, 2023

From CEL-SCI Corporation

Via Business Wire

Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

December 04, 2023

Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

December 04, 2023

Via Benzinga

Why Is Cancer Focused CEL-SCI Stock Trading Higher Today? ↗

December 04, 2023

CEL-SCI Corporation (AMEX: CVM) announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine (Leukocyte Interleukin, Injection) to be evaluated as the...

Via Benzinga

UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer

December 04, 2023

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock

November 20, 2023

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Pricing of $5 Million Offering of Common Stock

November 16, 2023

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Issues Letter to Shareholders

October 30, 2023

From CEL-SCI Corporation

Via Business Wire

Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments

October 24, 2023

EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END

Via FinancialNewsMedia

CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals

October 24, 2023

From CEL-SCI Corporation

Via Business Wire

5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023

October 23, 2023

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production

October 19, 2023

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer

October 05, 2023

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer

September 26, 2023

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results

August 11, 2023

From CEL-SCI Corporation

Via Business Wire

Stocks That Hit 52-Week Lows On Monday ↗

July 31, 2023

On Monday, 27 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

July 28, 2023

Friday's session saw 59 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

July 25, 2023

On Tuesday, 56 companies set new 52-week lows.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.